The caveat that comes before anything else
Methylene blue inhibits an enzyme (MAO-A) that antidepressants also target, so combining it with SSRIs, SNRIs, MAOIs, tramadol, or triptans can trigger serotonin syndrome — a reaction ranging from unpleasant to fatal. The FDA's boxed warning on the prescription formulation exists because this has happened to real patients. If you take an antidepressant, migraine medication, or opioid, this is off the table until you've cleared it with whoever prescribes it.
With that on the table: methylene blue is a 100-plus-year-old compound — a former textile dye, an old antimalarial, still FDA-approved for methemoglobinemia. Its life as a nootropic is a 2025 phenomenon — the timing lines up with a widely discussed Huberman Lab conversation with psychiatrist Chris Palmer about mitochondrial dysfunction, which appears to have helped push a niche compound onto supplement shelves, though how much of the surge traces to that one conversation versus wider podcast and social-media chatter isn't something we can verify. The mechanistic story — rerouting electrons around a stalled step in energy production — is genuinely interesting cell biology. Whether that produces a real cognitive benefit from a daily dropper is a different, unanswered question.
What the research says
Acute memory and attention (Grade B). The best human evidence is a 2016 Radiology study: a randomized, placebo-controlled fMRI trial in 26 healthy adults. A single low oral dose increased brain activity during attention and memory tasks and improved memory-retrieval accuracy by about 7% versus placebo, an hour post-dose. Real and well-designed — but one trial, 26 people, one dose, no independent replication.
Fear extinction and PTSD (Grade B, different context). Two RCTs from overlapping teams found a single dose given right after exposure-therapy sessions improved fear-extinction retention in claustrophobia patients, on average, and treatment response in PTSD patients. The claustrophobia result was conditional, not one-directional: participants who left the exposure session with low fear did better on methylene blue than placebo, but participants who left the session with moderate-to-high fear tended to do worse on methylene blue than placebo — meaning the same dose can help or hurt depending on how the session went. Legitimate trials, but adjunct-to-therapy findings under a supervised single-dose protocol — not evidence it sharpens a healthy person on an ordinary day.
Mitochondrial mechanism (Grade C — the trend's actual foundation). The idea behind the current wave is that methylene blue supports mitochondrial electron transport and cuts oxidative stress, benefiting energy-hungry tissue like neurons. That's well documented in cell and animal models of stroke, Alzheimer's, and traumatic brain injury — not tested as a driver of cognitive enhancement in healthy humans on a daily dose. The trend runs well ahead of this evidence.
Every human trial used a single dose, or a handful spaced across days, under supervision. None tested the product actually being sold: a daily dropper taken indefinitely by a healthy adult chasing focus. That gap between what's proven and what's marketed, layered on a serious drug-interaction risk, is why this earns a C despite three real RCTs.
How much, and which form
No trial has tested a daily maintenance dose. The clinical studies used one-time doses of roughly 0.5-4 mg/kg (about 35-280 mg for a 70 kg adult) under medical observation. The 5-20 mg/day range circulating in nootropic communities is an extrapolation, not a validated protocol.
Sourcing is the other major variable. Pharmaceutical (USP) grade is manufactured and tested for ingestion, at >99% purity with heavy metals below 10 ppm. Aquarium, dye, or lab-reagent grade isn't purified or tested for consumption and can carry meaningful heavy-metal contamination. If a product doesn't explicitly state USP or pharmaceutical grade with third-party testing, don't ingest it.
Safety & interactions
The FDA's boxed warning covers the serotonin syndrome risk above and specifies a 72-hour washout before resuming a serotonergic drug. Methylene blue is also contraindicated in G6PD deficiency, where it can trigger severe hemolytic anemia instead of its intended effect. Expect harmless but startling blue-green urine and stool, and be aware it can throw off pulse oximeter readings. Informational only, not medical advice — talk to a clinician first, especially with any antidepressant, MAOI, triptan, or opioid, G6PD deficiency, pregnancy, nursing, or a chronic condition.
How we picked the brand
With sourcing as the main safety variable, selection came down to verifiable purity: USP pharmaceutical grade with a stated purity percentage, GMP-certified/FDA-registered manufacturing, independent third-party testing, and clear per-serving dosing instead of a proprietary blend. That rules out anything sold for aquarium or lab use — it doesn't mean the compound is proven for daily nootropic use.